The Translational Breast Cancer Research Consortium was well represented at the 2024 San Antonio Breast Cancer Symposium (SABCS).  Presentations included:

Endocrine Response in Women with Invasive Lobular Carcinoma (TBCRC 037): A Multicenter Randomized Clinical Trial [Poster: PS18-09]

A Randomized Phase II Window-of-opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions (TBCRC 042) [Poster: P2-12-19]

MARGOT/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs paclitaxel/trastuzumab/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer [Oral Presentation: LB1-02]

TBCRC 056: A phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: Results from the ER+/HER2- cohort [Oral Presentation: RF3-01]

TBCRC 058: A Randomized Phase II Study of Enzalutamide, Enzalutamide with Mifepristone, and Treatment of Physician’s Choice in Patients with Androgen Receptor-Positive Metastatic Triple-Negative or Estrogen Receptor-Low Breast Cancer (NCT06099769) [Poster: P3-08-17]